Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis: Correlation with its paired bone marrow and standard disease markers

Cancer

Volumn 101, Issue 10, 2004, Pages 2303-2308

  Cheung, Irene Y ^a   Sahota, Arvind ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

GD2 synthase; Neuroblastoma; PAXgene blood RNA; Real time quantitative reverse transcriptase polymerase chain reaction

Indexed keywords

(3 IODOBENZYL)GUANIDINE; HOMOVANILLIC ACID; MESSENGER RNA; SYNTHETASE; TUMOR MARKER; VANILMANDELIC ACID;

ARTICLE; BLOOD; BONE MARROW; BONE MARROW METASTASIS; BONE SCINTISCANNING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; NEUROBLASTOMA CELL; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

BONE MARROW; BRAIN NEOPLASMS; HUMANS; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASM CIRCULATING CELLS; NEUROBLASTOMA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 7644232921     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20660     Document Type: Article

References (20)

1. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in Stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21:181-189.
2. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993;11:1466-1477.
3. Moss TJ, Sanders DG. Detection of neuroblastoma cells in blood. J Clin Oncol. 1990;8:736-740.
4. Lode HN, Handgretinger R, Schuermann U, et al. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer. 1997;33:2024-2030.
5. Burchill SA, Bradbury FM, Selby P, Lewis IJ. Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Eur J Cancer. 1995;31A:553-556.
6. Miyajima Y, Kato K, Numata SI, Kudo K, Horibe K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer. 1995; 75:2757-2761.
7. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in Stage IV neuroblastoma: a Children's Cancer Group study. J Clin Oncol. 2000;18:4067-4076.
8. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in Stage 4 neuroblastoma in children over 1 year. J Clin Oncol. 2001;19:1795-1801.
9. Faulkner LB, Tintori V, Tamburini A, et al. High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples. J Hematother. 1998;7:361-366.
10. Cheung IY, Cheung NK. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res. 1997;3: 821-826.
11. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol. 2003;21:1087-1093.
12. Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NK. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol. 2003;21: 3853-3858.
13. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem. 2002; 48:1883-1890.
14. Muller MC, Merx K, Weisser A, et al. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia. 2002;16:2395-2399.
15. Pahl A, Brune K. Gene expression changes in blood after phlebotomy: implications for gene expression profiling. Blood. 2002;100:1094-1095.
16. Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res. 2001;7:1698-1705.
17. Burchill SA, Lewis IJ, Selby P. Improved methods using the reverse transcriptase polymerase chain reaction to detect tumour cells. Br J Cancer. 1999;79:971-977.
18. Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem. 2003;49:104-112.
19. Tchirkov A, Paillard C, Halle P, et al. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res. 2003;12:435-442.
20. Cheung IY, Cheung NK, Ghossein RA, Satagopan JM, Bhattacharya S, Coit DG. Association between molecular detection of GAGE and survival in patients with malignant melanoma: a retrospective cohort study. Clin Cancer Res. 1999; 5:2042-2047.